Is Vertex Stock Still a Good Buy?
Over the past ten years or so, Vertex Pharmaceuticals (NASDAQ:…
Sell
14
APDN Quote, Financials, Valuation and Earnings
Last price:
$0.88
Seasonality move
:
-9.14%
Day range:
$0.86 - $0.92
52-week range:
$0.72 - $237.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.06x
P/B ratio:
0.08x
Volume:
639.4K
Avg. volume:
2.4M
1-year change:
-99.53%
Market cap:
$993.4K
Revenue:
$3.4M
EPS (TTM):
-$285.99
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
APDN
Applied DNA Sciences
|
$1.2M | -$3.00 | 27.47% | -98.87% | -- |
|
FONR
Fonar
|
-- | -- | -- | -- | -- |
|
OCX
OncoCyte
|
$126.8K | -$0.25 | -27.97% | -77.88% | $4.42 |
|
PRPH
ProPhase Labs
|
$2.5M | -$0.18 | -32.58% | -48.57% | $13.80 |
|
VCYT
Veracyte
|
$111M | $0.20 | 14.14% | -93.75% | $42.20 |
|
XWEL
XWELL
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
APDN
Applied DNA Sciences
|
$0.90 | -- | $993.4K | -- | $0.00 | 0% | 0.06x |
|
FONR
Fonar
|
$12.49 | -- | $79.1M | 10.86x | $0.00 | 0% | 0.79x |
|
OCX
OncoCyte
|
$3.12 | $4.42 | $89.2M | -- | $0.00 | 0% | 21.67x |
|
PRPH
ProPhase Labs
|
$0.34 | $13.80 | $14.2M | -- | $0.00 | 0% | 1.03x |
|
VCYT
Veracyte
|
$31.38 | $42.20 | $2.4B | 104.60x | $0.00 | 0% | 5.47x |
|
XWEL
XWELL
|
$0.82 | -- | $4.3M | -- | $0.00 | 0% | 0.11x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
APDN
Applied DNA Sciences
|
-- | 5.762 | -- | 4.28x |
|
FONR
Fonar
|
0.03% | 1.790 | 0.07% | 10.85x |
|
OCX
OncoCyte
|
-- | -0.940 | -- | 1.41x |
|
PRPH
ProPhase Labs
|
31.06% | -3.205 | 37.21% | 1.12x |
|
VCYT
Veracyte
|
-- | 3.539 | -- | 4.27x |
|
XWEL
XWELL
|
-- | -1.288 | -- | 1.72x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
APDN
Applied DNA Sciences
|
$684.1K | -$3M | -113.07% | -113.07% | -247.7% | -$3.4M |
|
FONR
Fonar
|
$9.7M | $2.4M | 4.95% | 4.95% | 11.92% | $1.5M |
|
OCX
OncoCyte
|
$595K | -$5.4M | -581.11% | -581.11% | -2253.1% | -$5.6M |
|
PRPH
ProPhase Labs
|
-$165K | -$7.9M | -47.22% | -59.59% | -252.29% | -$4.2M |
|
VCYT
Veracyte
|
$78.8M | $6M | 2.14% | 2.14% | 2.9% | $20.4M |
|
XWEL
XWELL
|
$2.1M | -$4.6M | -71.82% | -71.82% | -54.82% | -$3.8M |
Applied DNA Sciences vs. Competitors
-
Which has Higher Returns APDN or FONR?
Fonar has a net margin of -220.57% compared to Applied DNA Sciences's net margin of 7.87%. Applied DNA Sciences's return on equity of -113.07% beat Fonar's return on equity of 4.95%.
Company Gross Margin Earnings Per Share Invested Capital APDNApplied DNA Sciences57.17% -$28.00 $12.5M FONRFonar39.03% $0.29 $159M -
What do Analysts Say About APDN or FONR?
Applied DNA Sciences has a consensus price target of --, signalling upside risk potential of 166566.67%. On the other hand Fonar has an analysts' consensus of -- which suggests that it could fall by --. Given that Applied DNA Sciences has higher upside potential than Fonar, analysts believe Applied DNA Sciences is more attractive than Fonar.
Company Buy Ratings Hold Ratings Sell Ratings APDNApplied DNA Sciences0 1 0 FONRFonar0 0 0 -
Is APDN or FONR More Risky?
Applied DNA Sciences has a beta of 0.856, which suggesting that the stock is 14.433% less volatile than S&P 500. In comparison Fonar has a beta of 1.167, suggesting its more volatile than the S&P 500 by 16.736%.
-
Which is a Better Dividend Stock APDN or FONR?
Applied DNA Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fonar offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Applied DNA Sciences pays -- of its earnings as a dividend. Fonar pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios APDN or FONR?
Applied DNA Sciences quarterly revenues are $1.2M, which are smaller than Fonar quarterly revenues of $25M. Applied DNA Sciences's net income of -$2.6M is lower than Fonar's net income of $2M. Notably, Applied DNA Sciences's price-to-earnings ratio is -- while Fonar's PE ratio is 10.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Applied DNA Sciences is 0.06x versus 0.79x for Fonar. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income APDNApplied DNA Sciences0.06x -- $1.2M -$2.6M FONRFonar0.79x 10.86x $25M $2M
-
Which has Higher Returns APDN or OCX?
OncoCyte has a net margin of -220.57% compared to Applied DNA Sciences's net margin of -2255.11%. Applied DNA Sciences's return on equity of -113.07% beat OncoCyte's return on equity of -581.11%.
Company Gross Margin Earnings Per Share Invested Capital APDNApplied DNA Sciences57.17% -$28.00 $12.5M OCXOncoCyte40.04% -$1.93 -$12.3M -
What do Analysts Say About APDN or OCX?
Applied DNA Sciences has a consensus price target of --, signalling upside risk potential of 166566.67%. On the other hand OncoCyte has an analysts' consensus of $4.42 which suggests that it could grow by 41.56%. Given that Applied DNA Sciences has higher upside potential than OncoCyte, analysts believe Applied DNA Sciences is more attractive than OncoCyte.
Company Buy Ratings Hold Ratings Sell Ratings APDNApplied DNA Sciences0 1 0 OCXOncoCyte1 2 0 -
Is APDN or OCX More Risky?
Applied DNA Sciences has a beta of 0.856, which suggesting that the stock is 14.433% less volatile than S&P 500. In comparison OncoCyte has a beta of 0.973, suggesting its less volatile than the S&P 500 by 2.709%.
-
Which is a Better Dividend Stock APDN or OCX?
Applied DNA Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OncoCyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Applied DNA Sciences pays -- of its earnings as a dividend. OncoCyte pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios APDN or OCX?
Applied DNA Sciences quarterly revenues are $1.2M, which are smaller than OncoCyte quarterly revenues of $1.5M. Applied DNA Sciences's net income of -$2.6M is higher than OncoCyte's net income of -$33.5M. Notably, Applied DNA Sciences's price-to-earnings ratio is -- while OncoCyte's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Applied DNA Sciences is 0.06x versus 21.67x for OncoCyte. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income APDNApplied DNA Sciences0.06x -- $1.2M -$2.6M OCXOncoCyte21.67x -- $1.5M -$33.5M
-
Which has Higher Returns APDN or PRPH?
ProPhase Labs has a net margin of -220.57% compared to Applied DNA Sciences's net margin of -209.38%. Applied DNA Sciences's return on equity of -113.07% beat ProPhase Labs's return on equity of -59.59%.
Company Gross Margin Earnings Per Share Invested Capital APDNApplied DNA Sciences57.17% -$28.00 $12.5M PRPHProPhase Labs-5.25% -$0.35 $55.3M -
What do Analysts Say About APDN or PRPH?
Applied DNA Sciences has a consensus price target of --, signalling upside risk potential of 166566.67%. On the other hand ProPhase Labs has an analysts' consensus of $13.80 which suggests that it could grow by 3963.6%. Given that Applied DNA Sciences has higher upside potential than ProPhase Labs, analysts believe Applied DNA Sciences is more attractive than ProPhase Labs.
Company Buy Ratings Hold Ratings Sell Ratings APDNApplied DNA Sciences0 1 0 PRPHProPhase Labs0 0 0 -
Is APDN or PRPH More Risky?
Applied DNA Sciences has a beta of 0.856, which suggesting that the stock is 14.433% less volatile than S&P 500. In comparison ProPhase Labs has a beta of -0.562, suggesting its less volatile than the S&P 500 by 156.182%.
-
Which is a Better Dividend Stock APDN or PRPH?
Applied DNA Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProPhase Labs offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Applied DNA Sciences pays -- of its earnings as a dividend. ProPhase Labs pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios APDN or PRPH?
Applied DNA Sciences quarterly revenues are $1.2M, which are smaller than ProPhase Labs quarterly revenues of $3.1M. Applied DNA Sciences's net income of -$2.6M is higher than ProPhase Labs's net income of -$6.6M. Notably, Applied DNA Sciences's price-to-earnings ratio is -- while ProPhase Labs's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Applied DNA Sciences is 0.06x versus 1.03x for ProPhase Labs. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income APDNApplied DNA Sciences0.06x -- $1.2M -$2.6M PRPHProPhase Labs1.03x -- $3.1M -$6.6M
-
Which has Higher Returns APDN or VCYT?
Veracyte has a net margin of -220.57% compared to Applied DNA Sciences's net margin of 4.31%. Applied DNA Sciences's return on equity of -113.07% beat Veracyte's return on equity of 2.14%.
Company Gross Margin Earnings Per Share Invested Capital APDNApplied DNA Sciences57.17% -$28.00 $12.5M VCYTVeracyte66.39% $0.06 $1.2B -
What do Analysts Say About APDN or VCYT?
Applied DNA Sciences has a consensus price target of --, signalling upside risk potential of 166566.67%. On the other hand Veracyte has an analysts' consensus of $42.20 which suggests that it could grow by 34.48%. Given that Applied DNA Sciences has higher upside potential than Veracyte, analysts believe Applied DNA Sciences is more attractive than Veracyte.
Company Buy Ratings Hold Ratings Sell Ratings APDNApplied DNA Sciences0 1 0 VCYTVeracyte7 2 1 -
Is APDN or VCYT More Risky?
Applied DNA Sciences has a beta of 0.856, which suggesting that the stock is 14.433% less volatile than S&P 500. In comparison Veracyte has a beta of 2.032, suggesting its more volatile than the S&P 500 by 103.174%.
-
Which is a Better Dividend Stock APDN or VCYT?
Applied DNA Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Veracyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Applied DNA Sciences pays -- of its earnings as a dividend. Veracyte pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios APDN or VCYT?
Applied DNA Sciences quarterly revenues are $1.2M, which are smaller than Veracyte quarterly revenues of $118.6M. Applied DNA Sciences's net income of -$2.6M is lower than Veracyte's net income of $5.1M. Notably, Applied DNA Sciences's price-to-earnings ratio is -- while Veracyte's PE ratio is 104.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Applied DNA Sciences is 0.06x versus 5.47x for Veracyte. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income APDNApplied DNA Sciences0.06x -- $1.2M -$2.6M VCYTVeracyte5.47x 104.60x $118.6M $5.1M
-
Which has Higher Returns APDN or XWEL?
XWELL has a net margin of -220.57% compared to Applied DNA Sciences's net margin of -56.4%. Applied DNA Sciences's return on equity of -113.07% beat XWELL's return on equity of -71.82%.
Company Gross Margin Earnings Per Share Invested Capital APDNApplied DNA Sciences57.17% -$28.00 $12.5M XWELXWELL24.38% -$0.99 $14.8M -
What do Analysts Say About APDN or XWEL?
Applied DNA Sciences has a consensus price target of --, signalling upside risk potential of 166566.67%. On the other hand XWELL has an analysts' consensus of -- which suggests that it could grow by 752.22%. Given that Applied DNA Sciences has higher upside potential than XWELL, analysts believe Applied DNA Sciences is more attractive than XWELL.
Company Buy Ratings Hold Ratings Sell Ratings APDNApplied DNA Sciences0 1 0 XWELXWELL0 0 0 -
Is APDN or XWEL More Risky?
Applied DNA Sciences has a beta of 0.856, which suggesting that the stock is 14.433% less volatile than S&P 500. In comparison XWELL has a beta of 2.106, suggesting its more volatile than the S&P 500 by 110.579%.
-
Which is a Better Dividend Stock APDN or XWEL?
Applied DNA Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XWELL offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Applied DNA Sciences pays -- of its earnings as a dividend. XWELL pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios APDN or XWEL?
Applied DNA Sciences quarterly revenues are $1.2M, which are smaller than XWELL quarterly revenues of $8.4M. Applied DNA Sciences's net income of -$2.6M is higher than XWELL's net income of -$4.8M. Notably, Applied DNA Sciences's price-to-earnings ratio is -- while XWELL's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Applied DNA Sciences is 0.06x versus 0.11x for XWELL. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income APDNApplied DNA Sciences0.06x -- $1.2M -$2.6M XWELXWELL0.11x -- $8.4M -$4.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Okta Stock Finally Gaining Investor Confidence?
Given how digital transformation has proliferated, cyberattacks have also been…
Is The Trade Desk the Best Advertising Stock Now?
The worldly backdrop is now shrouded in heavy uncertainty and…
Stock Ideas
Buy
59
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
55
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
85
HIMS alert for Apr 30
Hims & Hers Health [HIMS] is down 5.39% over the past day.
Buy
54
EAT alert for Apr 30
Brinker International [EAT] is down 1.98% over the past day.
Sell
16
NSP alert for Apr 30
Insperity [NSP] is down 4.48% over the past day.
